Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A low-grade squamous cell carcinoma that arises from the conjunctiva. It is the most common primary malignant tumor that arises from the conjunctiva. It usually affects older white males. Excessive exposure to sunlight is a risk factor. Patients may present with a mass, red eye, or pain.
Biomarker and diagnostic research for conjunctival squamous cell carcinoma has been reported in the published literature.
2 clinical trials registered, 2 recruiting. Interventions under study include procedural interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
165 publications have been identified in PubMed for conjunctival squamous cell carcinoma. Research spans Case Report / Case Series (30%), Review / Meta-Analysis (18%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 50 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 4:38 AM UTC
Research summaries | 30 | 18% |
Disease patterns and progression | 30 | 18% |
Clinical study results | 17 | 10% |
Testing and diagnosis research | 14 | 8% |
Laboratory research | 11 | 7% |
New treatment approaches | 7 | 4% |
Other research | 6 | 4% |
Bowen RC (2026). [PMID: 41296343](https://pubmed.ncbi.nlm.nih.gov/41296343/). *JAMA ophthalmology*. [Clinical Trial Publication]
du Preez S (2026). [PMID: 41090548](https://pubmed.ncbi.nlm.nih.gov/41090548/). *Vet Ophthalmol*. [Case Report / Case Series]
Höllhumer R (2026). [PMID: 41772080](https://pubmed.ncbi.nlm.nih.gov/41772080/). *Eye (Lond)*. [Other]
Sakata R (2026). [PMID: 41748055](https://pubmed.ncbi.nlm.nih.gov/41748055/). *Am J Ophthalmol*. [Diagnostic / Biomarker]
Ghanbari H (2026). [PMID: 41975814](https://pubmed.ncbi.nlm.nih.gov/41975814/). *Diagnostics (Basel)*. [Review / Meta-Analysis]
Almobayed A (2026). [PMID: 41827158](https://pubmed.ncbi.nlm.nih.gov/41827158/). *J Clin Med*. [Review / Meta-Analysis]
Daryabari SH (2026). [PMID: 42047870](https://pubmed.ncbi.nlm.nih.gov/42047870/). *Int Ophthalmol*. [Review / Meta-Analysis]
Aslani A (2026). [PMID: 42106506](https://pubmed.ncbi.nlm.nih.gov/42106506/). *Eye (Lond)*. [Other]
Grigaite A (2026). [PMID: 41672421](https://pubmed.ncbi.nlm.nih.gov/41672421/). *Klinische Monatsblatter fur Augenheilkunde*. [Gene Therapy / Novel Therapeutics]
Gurnani B (2026). [PMID: 34424655](https://pubmed.ncbi.nlm.nih.gov/34424655/). *Unknown Journal*. [Review / Meta-Analysis]